Histotype-Tailored Neoadjuvant Chemotherapy versus Standard Chemotherapy in Patients with High-Risk Soft-Tissue Sarcomas (ISG-STS 1001): An International, Open-Label, Randomised, Controlled, Phase 3, Multicentre Trial.|Citation only
Histotype-Tailored Neoadjuvant Chemotherapy versus Standard Chemotherapy in Patients with High-Risk Soft-Tissue Sarcomas (ISG-STS 1001): An International, Open-Label, Randomised, Controlled, Phase 3, Multicentre Trial.|Citation only